<DOC>
	<DOCNO>NCT00061542</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy BETOPTIC S Timolol Gel-forming solution pediatric patient . Patients dose study drug 8 8 pm daily twelve week . Patients vision test , slit lamp exam , blood pressure pulse check visit . Patients dilate fundus exam corneal measurement take first last visit .</brief_summary>
	<brief_title>Safety Efficacy Study BETOPTIC S 0.25 % Timolol Gel-forming Solution 0.25 % 0.5 % Pediatric Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Betaxolol</mesh_term>
	<criteria>INCLUSION : Children 5 year old young require treatment glaucoma ocular hypertension whose vision 20/80 good cuptodisc ratio 0.8 less EXCLUSION : abnormal fixation IOP great 36 mm Hg significant retinal disease penetrate keratoplasty severe ocular pathology optic atrophy eye surgery past 30 day cardiovascular abnormality hypersensitivity beta blocker</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>